| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000011542 |
| Receipt No. | R000013490 |
| Official scientific title of the study | Development of human cellular models for motor neuron diseases using disease-specific induced pluripotent stem (iPS) cells |
| Date of disclosure of the study information | 2013/09/01 |
| Last modified on | 2018/03/06 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Development of human cellular models for motor neuron diseases using disease-specific induced pluripotent stem (iPS) cells | |
| Title of the study (Brief title) | Development of cellular models for motor neuron diseases from iPS cells | |
| Region |
|
|
| Condition | ||
| Condition | Adult-onset motor neuron diseases (MND) including sporadic or familial amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) type IV | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | In order to clarify pathomechanism underlying ALS/MND, patient-derived disease-specific iPS cells are generated and used to develop human cellular models reproducing the disease phenotype. |
| Basic objectives2 | Others |
| Basic objectives -Others | Biological property of neural cells differentiated from ALS/MND-specific iPS cells |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Biological property of cultured neural cells differentiated from ALS/MND-specific iPS cells, such as cellular morphology, neurite elongation, synaptogenesis, and action potentials |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | - Clinically diagnosed as sporadic/familial (hereditary) ALS or spinal muscular atrophy type IV, based on the guide to diagnosis and medical care by the Ministry of Health, Labour and Welfare, Japan
- Confirmed gene mutations in case of familial (hereditary) ALS - Obtained informed consent in writing |
|||
| Key exclusion criteria | - Presence of dementia
- Difficulty in sampling |
|||
| Target sample size | 20 | |||
| Research contact person | |
| Name of lead principal investigator | Masashi Aoki, MD, PhD |
| Organization | Tohoku University Graduate School of Medicine |
| Division name | Neurology |
| Address | 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan |
| TEL | +81-22-717-7000 |
| admin@neurol.med.tohoku.ac.jp | |
| Public contact | |
| Name of contact person | Hitoshi Warita, MD, PhD |
| Organization | Tohoku University Graduate School of Medicine |
| Division name | Neurology |
| Address | 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan |
| TEL | +81-22-717-7000 |
| Homepage URL | |
| warita-ns@umin.net | |
| Sponsor | |
| Institute | Tohoku University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP) and
Department of Physiology, Keio University School of Medicine |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 東北大学病院(宮城県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Partially published |
| URL releasing results | https://www.ncbi.nlm.nih.gov/pubmed/26997647 |
| Results | |
| Other related information | - observational study
- prospective study |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000013490 |